LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.16 -3.33

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.15

Максимум

1.21

Ключови измерители
By Trading Economics
Приходи	3.5M -20M
EPS	-0.32
Служители	49
EBITDA	6.8M -22M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+111.9% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	626K 75M
Предишно отваряне	4.49
Предишно затваряне	1.16

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.06.2026 г., 20:30 ч. UTC

Печалби

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

3.06.2026 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Garth Brooks Considers Sale of Music Catalog, Seeking Roughly $2 Billion -- WSJ

3.06.2026 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Brooks Had Been Entertaining a Deal for a Few Years, Sources Say -- WSJ

3.06.2026 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Brooks Seeking About $2 Billion for Rights to Songs, Recordings, Sources Say -- WSJ

3.06.2026 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Garth Brooks Considering Sale of Music Catalog, Sources Say -- WSJ

2.06.2026 г., 23:58 ч. UTC

Пазарно говорене

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2.06.2026 г., 23:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.06.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2.06.2026 г., 23:41 ч. UTC

Пазарно говорене

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2.06.2026 г., 23:01 ч. UTC

Придобивния, сливания и поглъщания

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2.06.2026 г., 23:01 ч. UTC

Придобивния, сливания и поглъщания

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2.06.2026 г., 23:00 ч. UTC

Придобивния, сливания и поглъщания

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2.06.2026 г., 22:57 ч. UTC

Пазарно говорене

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2.06.2026 г., 22:50 ч. UTC

Пазарно говорене

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2.06.2026 г., 21:07 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.06.2026 г., 21:07 ч. UTC

Пазарно говорене

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2.06.2026 г., 21:00 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

2.06.2026 г., 20:46 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:38 ч. UTC

Печалби

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2.06.2026 г., 20:21 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:12 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Product Rev $594M

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

111.9% нагоре

12-месечна прогноза

Среден 2.67 USD 111.9%

Висок 3 USD

Нисък 2 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.